Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aptose Bioscns (NQ: APTO ) 1.140 -0.010 (-0.88%) Streaming Delayed Price Updated: 10:56 AM EDT, May 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 38,429 Open 1.150 Bid (Size) 1.120 (4) Ask (Size) 1.140 (4) Prev. Close 1.150 Today's Range 1.100 - 1.150 52wk Range 1.110 - 6.000 Shares Outstanding 93,653,662 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024 May 14, 2024 APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Aptose Reports Results for the First Quarter 2024 May 14, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Performance YTD -52.11% -52.11% 1 Month -7.33% -7.33% 3 Month -41.54% -41.54% 6 Month -55.30% -55.30% 1 Year -80.65% -80.65% More News Read More Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 May 06, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Recap: Aptose Biosciences Q4 Earnings March 26, 2024 Via Benzinga Aptose Biosciences's Earnings: A Preview March 25, 2024 Via Benzinga Aptose Biosciences: Q3 Earnings Insights November 09, 2023 Via Benzinga APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023 March 26, 2024 Via InvestorPlace Aptose Reports Results for the Fourth Quarter and Full Year 2023 March 26, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 March 18, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option January 31, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Earnings Scheduled For March 26, 2024 March 26, 2024 Via Benzinga Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts January 26, 2024 Via InvestorPlace Topics Economy Workforce Exposures Economy Layoff Why Is SU Group (SUGP) Stock Moving Today? January 26, 2024 Via InvestorPlace Topics Initial Public Offering Exposures Securities Market Why Is Aptose Biosciences (APTO) Stock Down Today? January 26, 2024 Via InvestorPlace Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical January 26, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket January 26, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday January 26, 2024 Via InvestorPlace Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting December 09, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role November 30, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Reports Results for the Third Quarter 2023 November 09, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting November 02, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib October 30, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 30, 2023 Via Benzinga Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 October 26, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th October 23, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
